FOXP3 and head and neck squamous cell carcinoma: For example, one ongoing study (NCT04504669) is currently evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumour activity of anti-Foxp3 inhibitor AZD8701 alone and in combination with durvalumab (MEDI4736) in patients with selected advanced solid tumours, including HNSCC.